MedTrace Logo

MK-3475 Immunotherapy in Endometrial Carcinoma

NCT02630823 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-01-03

Study results available
· View outcomes & findings →

Summary

Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial biopsy as well as the surgical specimen post two cycles of pembrolizumab, the investigators will be able to evaluate the mechanism of action of this drug on the endometrial cancer tumor environment.

Conditions

Interventions

DRUG

MK-3475

PROCEDURE

Surgical resection (standard of care)

DRUG

Paclitaxel (standard of care)

DRUG

Carboplatin (standard of care)

RADIATION

Radiation (standard of care)

PROCEDURE

Endometrial biopsy

PROCEDURE

Peripheral blood draw

Sponsors & Collaborators

Principal Investigators

  • Premal Thaker, M.D., MSc. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-05
Primary Completion
2019-01-01
Completion
2020-10-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02630823 on ClinicalTrials.gov